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Abstract
Objective To externally validate a Genomic Classifier (GC) based risk-stratification nomogram identifying candidates who
would benefit from adjuvant radiation (aRT) therapy after radical prostatectomy (RP).
Methods We identified 350 patients who underwent RP, between 2013 and 2018, and had adverse pathological features
(positive margin, and/or pT3a or higher) on final pathology. Genomic profile was available for all these men. The clinical
recurrence-free survival was estimated using the Kaplan–Meier method. The external validity of the nomogram was tested
using the concordance index (c-index), calibration plot, and decision curve analysis.
Results The median follow-up of the cohort was 26.5 months. Overall, 14% of the patients received aRT. During the followup period, 3.4% of the patients developed metastasis. Overall 3-year metastasis-free survival was 95% (95% CI 0.92–0.98).
The c-index of the nomogram was 0.84. The calibration of the model was favorable. Decision-curve analysis showed a positive net benefit for probabilities ranging between 0.01 and 0.09, with the highest difference at threshold probability around
0.05. At that threshold, the net benefit is 0.06 for the model and 0 for treating all the patients.
Conclusion Our report is the first to confirm the validity of this genomic-based risk-stratification tool in identifying men
who might benefit from aRT after RP. As such, it can be a useful instrument to be incorporated in shared decision making
on whether administration of aRT will lead to a clinically meaningful benefit. Such a model can also be useful for patients’
classification in future clinical trials.
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* Firas Abdollah
firas.abdollah@gmail.com
1

Department of Surgery, Perelman School of Medicine
at the University of Pennsylvania, Philadelphia, USA

2

Department of Surgery, King Hussein Cancer Center,
Amman, Jordan

3

Vattikuti Urology Institute (VUI), Henry Ford Hospital,
Detroit, USA

4

Department of Pathology, Perelman School of Medicine
University of Pennsylvania, Philadelphia, USA

5

Department of Radiation Oncology, Perelman School
of Medicine University of Pennsylvania, Philadelphia, USA

6

Wayne State University, Detroit, USA

7

VUI Center for Outcomes Research Analytics
and Evaluation, Senior staff, Vattikuti Urology Institute
(VUI), Henry Ford Hospital, 2799 W Grand Blvd, Detroit,
MI 48202‑2689, USA

Introduction
In the past decade, the utilization of radical prostatectomy
(RP) for high-risk and locally advanced prostate cancer has
increased [1]. The risk of biochemical failure in this population ranges between 40 and 70%, which in turn increases
the risk of metastasis and prostate cancer-specific mortality
[2, 3]. Adjuvant radiation (aRT) improves progression-free
survival, as well as overall survival in patients with locally
advanced disease [4–8]. However, the number of patients
needed to be treated to prevent prostate cancer-specific
mortality is high, and aRT is associated with increased
treatment-related toxicity and decreased quality-adjusted
life expectancy [8]. Therefore, different prognostic nomograms were developed to optimize the post-operative management of prostate cancer patients. The majority of these
tools relied on tumor histopathological features and various
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prostate-specific antigen (PSA) measures and failed to
account for molecular heterogeneity of prostate cancer [9].
Recently, a Genomic Classifier (GC)-based risk-stratification tool was proposed to identify candidates for aRT therapy after RP [10]. It was developed using a historical cohort
of patients who underwent RP between 1990 and 2010. The
nomogram estimates the probability of clinical recurrence
(CR)-free survival after RP based on the following variables:
pathologic stage ≥ T3b, pathologic Gleason score ≥ 8, pathological lymph node invasion (LNI), and GC score ≥ 0.6. To
date, this nomogram has not been externally validated. This
is a crucial piece of information, which allows for assessing the accuracy of the model outside of its original development cohort, which can shed light on its clinical utility.
Moreover, the lack of external validation represents a limitation, as predictive models relying on historical data are not
necessarily generalizable to contemporary patients, who can
represent cohorts with different tumor burden, and possibly
have access to more contemporary and different treatment
options [11, 12]. Our study aimed to address this void and
test the external validity of the aforementioned model in a
contemporary cohort of men treated with robot-assisted RP
at a single, high-volume, tertiary care center.

Material and methods
Study population
We included a total of 350 patients who underwent robotassisted RP and bilateral pelvic lymph node dissection at a
single, high-volume, tertiary medical center between 2013
and 2018 and were found to have adverse pathological features on their final pathology specimen (positive margin,
and/or pT3a or higher), and reached undetectable PSA levels
after surgery. Genomic profile data was obtained for all the
patients. Data were prospectively collected in an institutional
review board approved a comprehensive database. The decision and the timing to administer aRT therapy and androgen
deprivation therapy were based on patient comorbidities and
life expectancy, patients’ treatment expectations, and consensus of our prostate cancer multidisciplinary team.

Covariates
The following variables were extracted for all patients: age
at diagnosis (years), serum PSA value at diagnosis (ng/mL),
pathological tumor stage (≤ pT2, pT3a,and pT3b) per AJCC
7th edition Classification [13], pathological Gleason score
(≤ 6, 7(3 + 4, 4 + 3), 8, and 9–10), surgical margin status
(negative or positive), pathological LNI status, receipt of
aRT or salvage radiotherapy (sRT), and GC score.
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Of note, aRT was defined as administering radiation at PSA
levels < 0.2 ng/mL within 12 months of surgery, while sRT
was defined when radiation is initiated at PSA level ≥ 0.2 ng/
mL or after 12 months of surgery. The prostatic fossa and
periprostatic tissues were irradiated to a mean dose of 70.2 Gy
using three-dimensional conformal RT, intensity-modulated
RT techniques, or proton therapy. GC scores were calculated
based on the pre-defined 22-marker Decipher classifier [14].
The GC score is a continuous score between 0 and 1, with the
lowest scores indicating a lower risk of metastasis. Patients
with GC > 0.6 were categorized as high risk; 0.45–0.6 as average risk; and < 0.45 as low risk [15].

Endpoint
Our endpoint consisted of CR, defined as evidence of disease
recurrence in the prostatic fossa, and/or radiographically on
computed tomography scan, bone scan, and/or other imaging modalities. Follow-up time was calculated from the time
of surgery to time of CR, or time of last available contact,
whichever occurred first. Patients who died without CR were
censored for the purpose of our analysis.

Statistical analysis
Medians and interquartile ranges (IQRs) were reported for
continuous variables, while proportions and frequencies
were reported for categorical variables. The Mann–WhitneyU test and chi-square tests were used to compare continuous
and categorical variables, respectively.
Kaplan–Meier curves were used to estimate CR rates
in the entire cohort and after stratifying patients based on
aRT status. The log-rank test was used to compare CR rates
between these groups.
Our statistical analysis consisted of several steps. First,
we used the time-dependent concordance index (c-index)
to examine the accuracy of the original model in our cohort
[16]. Second, calibration plots assessed the overall extent
of over-or-under-estimation of CR rates compared with the
nomogram-predicted probability of CR. Finally, the decision-curve analysis examined the net-benefit of using this
model in our cohort using the methodology described by
Vickers et al. [17].
All statistical analyses were performed using SAS 9.4
(SAS Institute, Cary, NC). Two-sided statistical significance
was defined as a p-value < 0.05.

Results
The median (IQR) follow-up of the cohort was 26.5
(17.48–36.44) months. The median age (IQR) of the cohort
was 64 (58–68) years. The median (IQR) PSA of the cohort
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was 5.9 (4.6–9) ng/mL. 19.6% of the cohort had Gleason
score 8 or higher. Non organ-confined disease (pT3a/b) was
noted in 238/350 (67.6%) of the cohort. A positive surgical
margin was documented in 337/350 (95.74%) of the patients.
Overall, 14% (49/350) of the patients received aRT. Patients
who received aRT had a higher GC score (0.8 vs. 0.5),
higher Gleason score 8 or above (55.1% vs.13.95%), higher
pathological stage (pT3b: 55.1% vs.14.6%), and a higher rate
of LNI (10.2% vs. 1.66%) compared with men treated with
initial observation (all P < 0.01) (Table1).
During the follow-up period, 12/350 (3.4%) of the
patients developed CR. Overall 3-year CR-free survival was
95% (95% confidence interval: 0.92–0.98). The 3-year CRfree survival was 0.88 (0.70–0.96) in patients who received
aRT compared to 0.97 (0.93–0.99) in those who were treated
with initial observation (p = 0.05) (Fig. 1) The predictive
accuracy of the nomogram for prediction of CR-free survival
was high in our set (c-Index 0.84), with favorable calibration characteristics (Fig. 2). Decision-curve analysis showed
a positive net benefit for probabilities range between 0.01
and 0.09, with the highest difference at threshold probability
around 0.05. At that threshold, the net benefit is 0.06 for the
model, and 0 for treating all the patients (Fig. 3).

Discussion
The management algorithm to administer aRT post-RP is
mainly geared by the presence of adverse pathological, postop PSA value, and PSA kinetics [8]. Nevertheless, aRT is

associated with increased treatment-related toxicity and
decreased quality-adjusted life expectancy. Subsequently,
only 30% of high-risk patients with a projected life expectancy of more than ten years received aRT therapy [18].
To better identify patients who might benefit the most from
administering aRT therapy, and avoiding overtreatment,
Dalela et al. developed a GC based risk-stratification tool,
which is the first tool that accounts tumor biology features
to direct the decision to administer aRT [10].
Compared to the original cohort, on which the nomogram
had been developed, patients in our study cohort were older
(64 vs. 61 years), had lower PSA at presentation (5.9 vs.
8.1 ng/mL), and had higher decipher score (0.5 vs. 0.41).
These differences emphasize the necessity of this study to
reflect the applicability of this nomogram in the current
practice.
This current study provides external validation of the GC
based risk-stratification tool using a contemporary cohort
of men who underwent RP between 2013 and 2018. The
predictive accuracy of the nomogram for the prediction of
CR-free survival was high in this cohort (c-Index = 0.84),
with optimal calibration characteristics. These findings support the validity of the abovementioned nomogram in its
ability to provide a clinically meaningful improvement in
the predictability of CR in contemporary practice.
Finally, the decision curve analysis showed that the model
has a significant net-benefit, and as such, can improve the
decision-making process in comparison to scenarios where
no patient gets aRT( more similar to the current practice),
or where all patients get aRT (more similar to the current

Table 1  Descriptive characteristics of 350 patients with prostate cancer treated with radical prostatectomy at a single, high-volume, tertiary
medical center between 2013 and 2018

Age, years, median (IQR)
BMI, Kg/m2, median (IQR)
Pre-operative PSA, ng/mL, median (IQR)
Decipher score
Pathological Gleason score, n (%)

Surgical Margin, n (%)

Pathological Staging N, n (%)
Pathological Staging T, n (%)

Grouping

Total cohort (N = 350)

No aRT (N = 301)

aRT (N = 49)

P-Value

6
7
8
≥9
Missing
Negative
Positive
N0
N1
≤ T2c
T3a
T3b

64 (58—68)
27.9 (25.1—30.6)
5.9 (4.6—9)
0.5 (0.3—0.7)
7 (1.%)
276 (78.41%)
43 (12.22%)
26 (7.39%)
2 (0.57%)
13 (3.69%)
337 (95.74%)
341 (96.88%)
11 (3.13%)
114 (32.39%)
166 (47.16%)
72 (20.45%)

64 (58—68)
27.6 (25.1—30.2)
5.8 (4.5—8.8)
0.5 (0.3—0.7)
7 (2.33%)
252 (83.72%)
26 (8.64%)
16 (5.32%)
2 (0.66%)
12 (3.99%)
287 (95.35%)
296 (98.34%)
5 (1.66%)
108 (35.88%)
149 (49.5%)
44 (14.62%)

65 (58—68)
30 (26.1—32.5)
6.4 (5—10.1)
0.8 (0.7—0.9)
0 (0%)
22 (44.9%)
17 (34.69%)
10 (20.41%)
0 (0%)
0 (0%)
49 (100%)
44 (89.8%)
5 (10.2%)
5 (10.2%)
17 (34.69%)
27 (55.1%)

0.26
0.01
0.19
< 0.001
< 0.001

NA

0.01
< .001

aRT, Adjuvant radiation therapy; BMI: Body mass index;
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Fig. 1  Kaplan-Meier curve
depicts the 3-year CR-free
survival in the cohort

Fig. 2  Calibration characteristics of the nomograms using the
contemporary data

recommendations, based on the aRT trial results) [7, 8].
Interestingly, there was no difference in the 3-year CR-free
survival in this cohort in patients who received aRT and
patients treated with initial observation. This might reflect
the current sagacious approach of offering aRT to patients
with several adverse pathological features and high GC
score. Meanwhile, observing patients with few adverse
pathological features and low GC score might be beneficial,
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along with treating patients with early sRT in the event
of biochemical progression as the case in 19.9%(60/301)
of the patients in the initial observation group. This
observation is in line with the results from the ARTISTIC metanalysis of three randomized trials, RADICALS
(ISRCTN40814031), GETUG-AFU 17 (NCT00667069),
and RAVES (NCT00860652),; which showed that early sRT
is not inferior to aRT [19].
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Fig. 3  Decision curves analysis plots measured at 36 months following radical prostectomy for clinical recurrence free survival

That said, it is noteworthy that the percentage of patients
with multiple adverse pathology features was very low in
these trials (~ 20%).These individuals are most likely to benefit from aRT rather than sRT, as previously demonstrated by
Abdollah et al. and Dalela et al. [10, 20]. The low percentage of these individuals in the ARTISTIC metanalysis limits
the applicability of its results. As such, the efficacy of early
sRT in patients with multiple adverse pathological features
remains to be demonstrated in future studies. Meanwhile, the
Dalela et al. nomogram can be a great tool to guide treatment
decision in these individuals.
Our study has several limitations that warrant discussion. For example, our patients were treated at a single,
high-volume, tertiary medical center; therefore, we cannot
exclude inherent selection bias due to referral pattern and
insurance coverage. Likewise, there was a wide variation in
the post-surgical treatment regime. Specifically, in addition
to the variation in the type of adjuvant radiotherapy offered
(e.g., external beam radiotherapy, intensity-modulated radiotherapy, and proton-beam radiotherapy), aRT was offered
under a range of conditions, including in combination with
androgen deprivation therapy, and whole pelvic radiation.
Finally, the short follow-up of this cohort represents another
limitation and precludes analysis of CR at later time points
(e.g., > 5 years).

Conclusions
Our Findings are the first to validate the GC-based stratification model proposed by Dalela et al. and shows its utility
in a contemporary setting. Moreover, our results show that
patients with multiple adverse pathology features and high
CG scores are most likely to benefit aRT rather than salvage
RT (sRT).This model can be used to advise patients in everyday clinical work, as well as to stratify patients for the
purpose of future randomized clinical trials, examining the
impact of post-operative radiotherapy.
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